Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Delay Differential Equation (DDE) Modeling of CAR-T Cellular Kinetics: Application to BCMA-Targeted (Ide-cel, Orva-cel) and CD19-Targeted (Liso-cel) Therapies

View through CrossRef
Abstract Chimeric antigen receptor (CAR) T-cell therapies undergo rapid in vivo expansion followed by contraction and variable long-term persistence after a single infusion, yielding cellular kinetic (CK) profiles that differ fundamentally from conventional small-molecule and biologic pharmacokinetics. Piecewise, phase-based CK models are widely used, but discontinuous switching and constant expansion assumptions can create numerical instability around the transition window and bias the characterization of early expansion and near-peak behavior. Building on our prior saturable expansion framework (Vmax/Km), we advanced CAR-T CK modeling by introducing (i) smooth S-shaped gating to replace discontinuous phase switching and enable continuous time-varying expansion dynamics, and (ii) delay differential equation (DDE) components to evaluate whether longitudinal data support explicit lags in downstream biological processes. Data were pooled from three CAR-T trials (TRANSCEND, KarMMa-3, and EVOLVE) spanning two BCMA-targeted products (ide-cel, orva-cel) and one CD19-targeted product (liso-cel). Models were estimated in Monolix using SAEM with importance sampling for final likelihood evaluation. Model selection relied on likelihood-based criteria (AIC, BIC, and Monolix BICc) and diagnostic assessments. Relative to a constant-expansion baseline, saturable expansion improved fit and reduced systematic model misspecification at high transgene levels (e.g., qPCR transgene copies/µg). Among multiple DDE placements evaluated, the data most strongly supported a delay on effector-to-memory conversion; delays in effector-like and/or memory-like decay were not favored. Simulations indicated that the conversion delay primarily modulated the timing and magnitude of the memory-like trajectory, with minimal impact on total-cell trajectories during the expansion phase at the evaluated scale. In a shared covariate framework with product as a categorical effect, BCMA-targeted products exhibited higher baseline levels and expansion capacity than liso-cel, with stronger evidence for slower effector-like decay for orva-cel than ide-cel. Overall, smooth-gated saturable expansion with DDE-based delayed conversion provides a parsimonious, biologically motivated framework for CAR-T CK and supports cross-product comparisons under harmonized structural assumptions.
Title: Delay Differential Equation (DDE) Modeling of CAR-T Cellular Kinetics: Application to BCMA-Targeted (Ide-cel, Orva-cel) and CD19-Targeted (Liso-cel) Therapies
Description:
Abstract Chimeric antigen receptor (CAR) T-cell therapies undergo rapid in vivo expansion followed by contraction and variable long-term persistence after a single infusion, yielding cellular kinetic (CK) profiles that differ fundamentally from conventional small-molecule and biologic pharmacokinetics.
Piecewise, phase-based CK models are widely used, but discontinuous switching and constant expansion assumptions can create numerical instability around the transition window and bias the characterization of early expansion and near-peak behavior.
Building on our prior saturable expansion framework (Vmax/Km), we advanced CAR-T CK modeling by introducing (i) smooth S-shaped gating to replace discontinuous phase switching and enable continuous time-varying expansion dynamics, and (ii) delay differential equation (DDE) components to evaluate whether longitudinal data support explicit lags in downstream biological processes.
Data were pooled from three CAR-T trials (TRANSCEND, KarMMa-3, and EVOLVE) spanning two BCMA-targeted products (ide-cel, orva-cel) and one CD19-targeted product (liso-cel).
Models were estimated in Monolix using SAEM with importance sampling for final likelihood evaluation.
Model selection relied on likelihood-based criteria (AIC, BIC, and Monolix BICc) and diagnostic assessments.
Relative to a constant-expansion baseline, saturable expansion improved fit and reduced systematic model misspecification at high transgene levels (e.
g.
, qPCR transgene copies/µg).
Among multiple DDE placements evaluated, the data most strongly supported a delay on effector-to-memory conversion; delays in effector-like and/or memory-like decay were not favored.
Simulations indicated that the conversion delay primarily modulated the timing and magnitude of the memory-like trajectory, with minimal impact on total-cell trajectories during the expansion phase at the evaluated scale.
In a shared covariate framework with product as a categorical effect, BCMA-targeted products exhibited higher baseline levels and expansion capacity than liso-cel, with stronger evidence for slower effector-like decay for orva-cel than ide-cel.
Overall, smooth-gated saturable expansion with DDE-based delayed conversion provides a parsimonious, biologically motivated framework for CAR-T CK and supports cross-product comparisons under harmonized structural assumptions.

Related Results

Fine Tuning Bispecific Activity in CLL: Harmonizing a CD19/20-T Cell Bispecific with a CD28 or 4-1BBL Costimulatory Bispecific
Fine Tuning Bispecific Activity in CLL: Harmonizing a CD19/20-T Cell Bispecific with a CD28 or 4-1BBL Costimulatory Bispecific
Introduction: T cell bispecific antibodies (TCBs), such as blinatumomab, mosunetuzumab or glofitamab, redirect T cells toward cancer cells and rely on endogenous T c...
Abstract 3833: SEA-BCMA: A highly active enhanced antibody for multiple myeloma
Abstract 3833: SEA-BCMA: A highly active enhanced antibody for multiple myeloma
Abstract Despite a number of new therapies for multiple myeloma (MM) most patients relapse, require multiple lines of therapy, and ultimately succumb to disease. The...
Evaluation of Anti-CAR Linker mAbs for CAR T Monitoring After BiTEs/bsAbs and CAR T-cell Pretreatment.
Evaluation of Anti-CAR Linker mAbs for CAR T Monitoring After BiTEs/bsAbs and CAR T-cell Pretreatment.
For monitoring of chimeric antigen receptor (CAR) T-cell therapies antigen-based CAR detection methods are usually applied. However, for each target-antigen a separate detection sy...
Modeling Elk Nutrition and Habitat Use in Western Oregon and Washington
Modeling Elk Nutrition and Habitat Use in Western Oregon and Washington
ABSTRACTStudies of habitat selection and use by wildlife, especially large herbivores, are foundational for understanding their ecology and management, especially if predictors of ...
Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
Ciltacabtagene autoleucel (also known as cilta-cel) is a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) on the surface of cancer cells...
Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma
Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma
Abstract Introduction: B cell maturation antigen (BCMA) is a novel target for T cell immunotherapy in MM including bispecific antibody (bsAb) and chimeric antigen re...
All-Trans Retinoic Acid Enhances CS1-BCMA Dual-Target CAR-T Cells in Multiple Myeloma
All-Trans Retinoic Acid Enhances CS1-BCMA Dual-Target CAR-T Cells in Multiple Myeloma
Background:CS1-BCMA dual-target chimeric antigen receptor T cell (CAR-T) has exhibited superior efficacy in multiple myeloma (MM). However, there are still obstacles such as target...

Back to Top